Henric Bjarke joined Tenpoint in October of 2024. With over 20 years of global executive experience in startup and large environments, Henric has held commercial and operational leadership positions at companies including Inozyme Pharma, Ophthotech, Alexion Pharmaceuticals, (OSI) Eyetech, and Pharmacia. Having built and led teams in North America and Europe, he has had five major product launches, of which three were blockbusters including Xalatan for Glaucoma. Henric also established the Intravitreal injection market while launching the first anti-VEGF for wet AMD, as well as has raised private and public capital over $300M including a $128M IPO.
Mr. Bjarke received a B.A. Sc. in business administration and economics from Uppsala University in Sweden.
